Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway

被引:162
作者
Chiu, David Kung-Chun [1 ]
Tse, Aki Pui-Wah [1 ]
Law, Cheuk-Ting [1 ]
Xu, Iris Ming-Jing [1 ]
Lee, Derek [1 ]
Chen, Mengnuo [1 ]
Lai, Robin Kit-Ho [1 ]
Yuen, Vincent Wai-Hin [1 ]
Cheu, Jacinth Wing-Sum [1 ]
Ho, Daniel Wai-Hung [1 ,2 ]
Wong, Chun-Ming [1 ,2 ]
Zhang, Huafeng [3 ]
Ng, Irene Oi-Lin [1 ,2 ]
Wong, Carmen Chak-Lui [1 ,2 ]
机构
[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
[3] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China
关键词
INDUCIBLE FACTOR-I; PARKINSONS-DISEASE; OXIDATIVE STRESS; PINK1; DEHYDROGENASE; KINASE; GROWTH; RESPIRATION; PHYSIOLOGY; EXPRESSION;
D O I
10.1038/s41419-019-2155-3
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Hypoxia is commonly found in cancers. Hypoxia, due to the lack of oxygen (O-2) as the electron recipient, causes inefficient electron transfer through the electron transport chain at the mitochondria leading to accumulation of reactive oxygen species (ROS) which could create irreversible cellular damages. Through hypoxia-inducible factor 1 (HIF-1) which elicits various molecular events, cells are able to overcome low O-2. Knowledge about the new molecular mechanisms governed by HIF-1 is important for new therapeutic interventions targeting hypoxic tumors. Using hepatocellular carcinoma (HCC) as a model, we revealed that the HIF-1 and the Notch signaling pathways cross-talk to control mitochondrial biogenesis of cancer cells to maintain REDOX balance. From transcriptome sequencing, we found that HEY1, a transcriptional repressor, in the NOTCH pathway was consistently induced by hypoxia in HCC cell lines. We identified a strong hypoxia response element (HRE) in HEY1 by chromatin immunoprecipitation (ChIP) and luciferase reporter assays. Transcriptome and ChIP sequencing further identified PINK1, a gene essential for mitochondrial biogenesis, as a novel transcriptional target of HEY1. HCC cells with HEY1 knockdown re-expressed PINK1. HEY1 and PINK1 expressions inversely correlated in human HCC samples. Overexpression of HEY1 and underexpression of PINK1 were detected in human HCC and associated with poor clinical outcomes. Functionally, we found that overexpression of HEY1 or knockdown of PINK1 consistently reduced mitochondrial cristae, mitochondrial mass, oxidative stress level, and increased HCC growth.
引用
收藏
页数:16
相关论文
共 52 条
[1]
PINK1 Kinase Catalytic Activity Is Regulated by Phosphorylation on Serines 228 and 402 [J].
Aerts, Liesbeth ;
Craessaerts, Katleen ;
De Strooper, Bart ;
Morais, Vanessa A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (05) :2798-2811
[2]
PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma [J].
Agnihotri, Sameer ;
Golbourn, Brian ;
Huang, Xi ;
Remke, Marc ;
Younger, Susan ;
Cairns, Rob A. ;
Chalil, Alan ;
Smith, Christian A. ;
Krumholtz, Stacey-Lynn ;
Mackenzie, Danielle ;
Rakopoulos, Patricia ;
Ramaswamy, Vijay ;
Taccone, Michael S. ;
Mischel, Paul S. ;
Fuller, Gregory N. ;
Hawkins, Cynthia ;
Stanford, William L. ;
Taylor, Michael D. ;
Zadeh, Gelareh ;
Rutka, James T. .
CANCER RESEARCH, 2016, 76 (16) :4708-4719
[3]
PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xL and impairing its pro-apoptotic cleavage [J].
Arena, G. ;
Gelmetti, V. ;
Torosantucci, L. ;
Vignone, D. ;
Lamorte, G. ;
De Rosa, P. ;
Cilia, E. ;
Jonas, E. A. ;
Valente, E. M. .
CELL DEATH AND DIFFERENTIATION, 2013, 20 (07) :920-930
[4]
The quest for the 1p36 tumor suppressor [J].
Bagchi, Anindya ;
Mills, Alea A. .
CANCER RESEARCH, 2008, 68 (08) :2551-2556
[5]
Notch signalling: a simple pathway becomes complex [J].
Bray, Sarah J. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (09) :678-689
[6]
Bruix J., 2016, EUR SOC MED ONC EMSO
[7]
Novel Basic Helix-Loop-Helix Transcription Factor Hes4 Antagonizes the Function of Twist-1 to Regulate Lineage Commitment of Bone Marrow Stromal/Stem Cells [J].
Cakouros, Dimitrios ;
Isenmann, Sandra ;
Hemming, Sarah Elizabeth ;
Menicanin, Danijela ;
Camp, Esther ;
Zannetinno, Andrew Christopher William ;
Gronthos, Stan .
STEM CELLS AND DEVELOPMENT, 2015, 24 (11) :1297-1308
[8]
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[9]
WHAT GENETICS TELLS US ABOUT THE CAUSES AND MECHANISMS OF PARKINSON'S DISEASE [J].
Corti, Olga ;
Lesage, Suzanne ;
Brice, Alexis .
PHYSIOLOGICAL REVIEWS, 2011, 91 (04) :1161-1218
[10]
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502